The estimated Net Worth of Charles L Cooney is at least $499 dollars as of 16 February 2023. Charles Cooney owns over 8,750 units of Codiak BioSciences stock worth over $499 and over the last 4 years Charles sold CDAK stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Charles Cooney CDAK stock SEC Form 4 insiders trading
Charles has made over 1 trades of the Codiak BioSciences stock since 2023, according to the Form 4 filled with the SEC. Most recently Charles exercised 8,750 units of CDAK stock worth $499 on 16 February 2023.
The largest trade Charles's ever made was exercising 8,750 units of Codiak BioSciences stock on 16 February 2023 worth over $499. On average, Charles trades about 1,750 units every 0 days since 2020. As of 16 February 2023 Charles still owns at least 8,750 units of Codiak BioSciences stock.
You can see the complete history of Charles Cooney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Cooney's mailing address?
Charles's mailing address filed with the SEC is C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140.
Insiders trading at Codiak BioSciences
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch..., and Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
What does Codiak BioSciences do?
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Codiak BioSciences's logo look like?
Complete history of Charles Cooney stock trades at Codiak BioSciences
Codiak BioSciences executives and stock owners
Codiak BioSciences executives and other stock owners filed with the SEC include:
-
Dr. Douglas Edward Williams Ph.D.,
Pres, CEO & Director -
Dr. Sriram Sathyanarayanan Ph.D.,
Chief Scientific Officer -
Yalonda Howze,
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. -
Dr. Benny Sorensen M.D., Ph.D.,
Member of Scientific Advisory Board & Consultant -
Dr. David J. Mauro M.D., Ph.D.,
Chief Medical Officer -
Dr. Benny Sorensen,
Member of Scientific Advisory Board & Consultant -
Richard Brudnick,
Chief Bus. Officer & Head of Corp. Strategy -
Nicole Barna,
Sr. VP of HR -
Christopher J. M. Taylor,
VP of Investor Relations & Corp. Communications -
Dr. Konstantin Konstantinov,
Chief Technology Officer -
Linda Cathavina Bain CPA,
CFO & Treasurer -
Arundathy N. Pandite,
Director -
Anne Virginie Eggimann,
Director -
Ventures Fund V General Par...,
-
Richard Brudnick,
See Remarks -
Venture Fund Viii, L.P.Arch...,
-
Charles L Cooney,
Director -
Kyriazi Theo Melas,
Director -
Briggs Morrison,
Director -
Eric S Lander,
Director -
Jason Haddock,
Director -
Karen Bernstein,
Director -
Steven Gillis,
Director -
Permanent Fund Corp Alaska,
-
Benny Sorensen,
See Remarks -
Nicole Barna,
See Remarks -
Jennifer J. Wheler,
Chief Medical Officer -
Ajay Verma,
See Remarks -
David J Mauro,
Chief Medical Officer -
Douglas E Williams,
President & CEO -
Konstantin Konstantinov,
Chief Technology Officer -
Linda Bain,
Chief Financial Officer -
Sriram Sathyanarayanan,
Chief Scientific Officer -
Yalonda Howze,
See Remarks